232 related articles for article (PubMed ID: 28374813)
1. Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.
Krishnamoorthi R; Lewis JT; Krishna M; Crews NJ; Johnson ML; Dierkhising RA; Ginos BF; Wang KK; Wolfsen HC; Fleischer DE; Ramirez FC; Buttar NS; Katzka DA; Iyer PG
Am J Gastroenterol; 2017 Jun; 112(6):867-873. PubMed ID: 28374813
[TBL] [Abstract][Full Text] [Related]
2. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
3. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
6. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
7. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
8. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
[TBL] [Abstract][Full Text] [Related]
9. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
10. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
[TBL] [Abstract][Full Text] [Related]
11. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
[TBL] [Abstract][Full Text] [Related]
12. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
[TBL] [Abstract][Full Text] [Related]
13. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
14. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
[TBL] [Abstract][Full Text] [Related]
15. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
[TBL] [Abstract][Full Text] [Related]
16. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
17. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
18. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
19. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
20. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
